BioCorRx's Lucemyra Acquisition Raises Revenue but Liquidity, Going-Concern Risks Persist

BioCorRx Inc. (OTCMKTS: BICX) - quick read

What's happening inside: BioCorRx completed an asset acquisition (Lucemyra) on March 4, 2025, recognized sizeable intangible assets and goodwill, began supply/distribution sales from that acquisition, continued NIH grant-funded R&D, and has been financing operations largely through related‑party and third‑party promissory notes and equity issuances. Management reports substantial doubt about going concern and continues to convert debt and issue equity to fund operations.

Key facts & statistics (reported June 30, 2025)
- Cash: $111,872.
- Total assets: $6,680,879; Total liabilities: $19,694,108.
- Working capital deficit: $(14,031,643).
- Accounts payable & accrued expenses (including related party payables $1,629,743): $11,805,777.
- Notes payable (total): $1,546,514; Notes payable - related parties: $1,108,559.
- Intangible assets, net: $3,080,422; Goodwill: $2,840,400 (from Lucemyra APA).
- Inventory (finished goods): $133,597 (June 30, 2025).
- Grant receivable: $153,728; Deferred grant revenue: $56,590.
- Revenues (Q2 2025): $178,238; Six months 2025: $313,137 (vs $4,045 and $7,665 in comparable 2024 periods).
- Grant income Q2 2025: $154,270 (Q2 2024: $518,667). Six months 2025: $568,249 (2024: $631,630).
- Loss from operations Q2 2025: $(1,413,920). Net loss Q2 2025: $(1,377,276); attributable to BioCorRx: $(1,233,418).
- Six months net loss: $(2,229,040); attributable to BioCorRx: $(2,074,825).
- Net loss per share basic & diluted Q2 2025: $(0.07); six months: $(0.13).
- Shares outstanding June 30, 2025: 17,281,886 (note: filing reports 18,911,994 shares outstanding as of Aug 8, 2025).
- Acquisition consideration (Lucemyra): fair value total $828,076; identified net assets negative $2,012,324; goodwill $2,840,400; acquisition-related costs recognized $219,359.

Inside the company - operational highlights
- Lucemyra acquisition (Mar 4, 2025) drives near-term commercial revenue: supply & distribution sales contributed $176,448 in Q2 and $311,347 YTD.
- NIH/NIDA grants remain a material funding source (U01 award of $11,029,977 announced Mar 1, 2024) - grant reimbursements are recognized as costs are incurred.
- R&D expense declined YoY (six months: $458,779 in 2025 vs $750,196 in 2024) reflecting lower spend in current period.
- SG&A rose materially (six months SG&A $2,109,404 vs $1,580,419 in 2024) - consulting, accounting & legal up sharply.
- Non-cash charges and remeasurements: large amortization of customer base and royalty/contingent consideration fair value adjustments; debt extinguishment and loss on settlement recorded in 2025.
- Financing: related‑party advances of $847,700 received during the six months; multiple note amendments and debt-for-equity exchanges (large share issuances to settle/convert debt).
- Governance/controls: management disclosed material weaknesses in internal controls and limited GAAP experience in complex transactions.

Positive aspects of the income statement
- Revenue pick‑up: commercial sales from the Lucemyra asset materially increased revenues compared with prior year (Q2 +4,306% YoY; six months +3,985% YoY).
- Grant income continues to offset R&D and clinical work (YTD grant income $568,249).
- R&D expense is down YoY, reducing cash burn from operations attributable to lower trial or study outlays this period.
- Interest and non‑related interest expense (amortization of debt discounts) declined YoY, lowering financing cost reported in 2025 vs 2024.

Negative aspects of the income statement
- Persistent losses: net loss attributable to BioCorRx of $(2.07M) YTD; Q2 loss remained >$1.2M - the company is not profitable and losses continue.
- SG&A spike: selling, general & administrative costs (YTD $2.11M) rose significantly driven by consulting, legal and acquisition costs - pressure on operating margin.
- Grant income decreased vs prior-year periods (Q2 grant income $154k vs $518k prior), reducing a non-dilutive funding cushion.
- Large non-cash amortization: intangible amortization and goodwill from the Lucemyra purchase inflate operating expense (depreciation & amortization Q2 $71,977; YTD $96,820).
- Material one‑time charges: loss on settlement/extinguishment of debt ($187,514 YTD) and acquisition-related costs ($219,359) worsen reported losses.
- Concentration risk: two customers represented 99% of revenue and 100% of accounts receivable at June 30, 2025 - high customer concentration.
- Going concern: management explicitly states substantial doubt about the company's ability to continue for 12 months without additional capital.

Risks & near-term catalysts
- Risks: heavy reliance on related‑party financing, large accounts payable and accruals, legal exposure (settlement with Pellecome $418,000 with $258,000 outstanding as of Jun 30, 2025; a qui tam complaint reported July 2025), and control weaknesses.
- Catalysts that could reduce uncertainty: additional grant draws from NIDA/U01 funding, successful commercialization growth of Lucemyra distribution, completion of financing tranche (noted July 29, 2025 securities purchase $350,000), or meaningful debt conversions that reduce interest and cash obligations.

Bottom line: BioCorRx (OTCMKTS: BICX) is transitioning from pure R&D toward commercial sales via the March 2025 Lucemyra asset purchase, which materially increased revenue in the quarter. However, the company remains loss-making, highly leveraged, dependent on related‑party financing and grants, and faces liquidity and legal risks. Watch cash runway, grant funding cadence, Lucemyra sales growth, and any further debt-to-equity conversions as the primary drivers that will determine near‑term survivability and valuation.